Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Academic Article uri icon

Overview

abstract

  • The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC). Here, we use programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) and transcriptome analysis to evaluate the association of immune and angiogenesis pathways, and molecular subtypes, with overall survival (OS) in UC. Higher PD-L1 IHC and immune pathway scores, but not angiogenesis scores, are associated with greater ramucirumab OS benefit. Additionally, Basal subtypes, which have higher PD-L1 IHC and immune/angiogenesis pathway scores, show greater ramucirumab OS benefit compared to Luminal subtypes, which have relatively lower scores. Multivariable analysis suggests patients from East Asia as having lower immune/angiogenesis signature scores, which correlates with decreased ramucirumab OS benefit. Our data highlight the utility of multiple biomarkers including PD-L1, molecular subtype, and immune phenotype in identifying patients with UC who might derive the greatest benefit from treatment with ramucirumab.

publication date

  • April 6, 2022

Research

keywords

  • Carcinoma, Transitional Cell
  • Urinary Bladder Neoplasms

Identity

PubMed Central ID

  • PMC8987042

Scopus Document Identifier

  • 85127624381

Digital Object Identifier (DOI)

  • 10.1038/s41467-022-29441-y

PubMed ID

  • 35388003

Additional Document Info

volume

  • 13

issue

  • 1